Almirall S.A. unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that underscores its commitment to advancing the wellbeing of psoriasis patients and their families through treatments and cutting-edge research. The data presented in posters showed that Ilumetri (tildrakizumab) significantly improved the wellbeing of psoriasis patients, as well as the wellbeing of their relatives.2 New evidence presented in the POSITIVE study, the first clinical study in dermatology to assess improvements in patients? wellbeing as a primary endpoint, reveals that around 40% of the patients with moderate-to-severe plaque psoriasis showed depressive symptoms at baseline.1In this regard,tildrakizumab for the first time demonstrated improvement in patients?

wellbeing, achieving similar levels to the general population after 16 weeks, which was maintained up to week 28.1 Additionally, tildrakizumab reassures its effectiveness, improving also patients? health-related quality of life (HRQoL), with high rates of treatment satisfaction in patients with moderate-to-severe plaque psoriasis after 28 weeks in a real-world setting,3 with no new safety signals and a reassuring safety profile5 consistent with previous randomized clinical trials (RCT) and real-world studies. This study demonstrates for the first time the impact of patient's psoriasis on the social and emotional wellbeing of their relatives, underscoring the existing unmet needs not only in the management of psoriatic patients but also their families.

Tildrakizumab significantly improved relatives? wellbeing after 28 weeks. The new evidences on the TRIBUTE study demonstrated that tildrakizumab improved other important patient-reported outcomes (PROs) such as sleep quality, which is highly correlated with itch, pain, quality of life, and work productivity and not with PASI.

The results also revealed that tildrakizumab demonstrated similar efficacy and safety regardless of the baseline characteristics of the patients. These new data highlight the importance of evaluating other endpoints beyond skin symptoms to ensure a holistic approach to psoriasis management. Almirall also reported results from the TILOT study that demonstrated sustained efficacy and safety of tildrakizumab over 2 years in patients with moderate-to-severe plaque psoriasis in routine clinical practice including sensitive areas and improvements of itch.

This was reflected in significant improvements in all measured parameters, including treatment satisfaction and quality of life.